110 related articles for article (PubMed ID: 29315012)
1. Development of an Anti-HER2 Monoclonal Antibody H2Mab-139 Against Colon Cancer.
Kaneko MK; Yamada S; Itai S; Kato Y
Monoclon Antib Immunodiagn Immunother; 2018 Feb; 37(1):59-62. PubMed ID: 29315012
[TBL] [Abstract][Full Text] [Related]
2. Establishment of H
Yamada S; Itai S; Nakamura T; Chang YW; Harada H; Suzuki H; Kaneko MK; Kato Y
Monoclon Antib Immunodiagn Immunother; 2017 Dec; 36(6):287-290. PubMed ID: 29172998
[TBL] [Abstract][Full Text] [Related]
3. H
Itai S; Fujii Y; Kaneko MK; Yamada S; Nakamura T; Yanaka M; Saidoh N; Chang YW; Handa S; Takahashi M; Suzuki H; Harada H; Kato Y
Monoclon Antib Immunodiagn Immunother; 2017 Aug; 36(4):143-148. PubMed ID: 28700270
[TBL] [Abstract][Full Text] [Related]
4. Anti-Human Epidermal Growth Factor Receptor 2 Monoclonal Antibody H
Kato Y; Ohishi T; Yamada S; Itai S; Takei J; Sano M; Nakamura T; Harada H; Kawada M; Kaneko MK
Monoclon Antib Immunodiagn Immunother; 2019 Aug; 38(4):157-161. PubMed ID: 31199696
[TBL] [Abstract][Full Text] [Related]
5. An Anti-Human Epidermal Growth Factor Receptor 2 Monoclonal Antibody H
Kato Y; Ohishi T; Takei J; Nakamura T; Sano M; Asano T; Sayama Y; Hosono H; Kawada M; Kaneko MK
Monoclon Antib Immunodiagn Immunother; 2020 Aug; 39(4):123-128. PubMed ID: 32552424
[TBL] [Abstract][Full Text] [Related]
6. An Antihuman Epidermal Growth Factor Receptor 2 Monoclonal Antibody (H
Kato Y; Ohishi T; Takei J; Nakamura T; Kawada M; Kaneko MK
Monoclon Antib Immunodiagn Immunother; 2020 Aug; 39(4):135-139. PubMed ID: 32644843
[TBL] [Abstract][Full Text] [Related]
7. An Anti-HER2 Monoclonal Antibody H
Tateyama N; Asano T; Ohishi T; Takei J; Hosono H; Nanamiya R; Tanaka T; Sano M; Saito M; Kawada M; Kaneko MK; Kato Y
Monoclon Antib Immunodiagn Immunother; 2021 Aug; 40(4):184-190. PubMed ID: 34424760
[TBL] [Abstract][Full Text] [Related]
8. H
Kato Y; Ohishi T; Sano M; Asano T; Sayama Y; Takei J; Kawada M; Kaneko MK
Monoclon Antib Immunodiagn Immunother; 2020 Jun; 39(3):61-65. PubMed ID: 32423281
[TBL] [Abstract][Full Text] [Related]
9. Development of a Novel Anti-HER2 Monoclonal Antibody H
Takei J; Asano T; Tanaka T; Sano M; Hosono H; Nanamiya R; Tateyama N; Saito M; Suzuki H; Harada H; Kaneko MK; Kato Y
Monoclon Antib Immunodiagn Immunother; 2021 Aug; 40(4):168-176. PubMed ID: 34424764
[TBL] [Abstract][Full Text] [Related]
10. Establishment of a Novel Cancer-Specific Anti-HER2 Monoclonal Antibody H
Kaneko MK; Suzuki H; Kato Y
Monoclon Antib Immunodiagn Immunother; 2024 Apr; 43(2):35-43. PubMed ID: 38563783
[TBL] [Abstract][Full Text] [Related]
11. H
Takei J; Kaneko MK; Ohishi T; Kawada M; Harada H; Kato Y
Exp Ther Med; 2020 Aug; 20(2):846-853. PubMed ID: 32765652
[TBL] [Abstract][Full Text] [Related]
12. Epitope Mapping of an Anti-HER2 Monoclonal Antibody (H
Asano T; Takei J; Suzuki H; Kaneko MK; Kato Y
Monoclon Antib Immunodiagn Immunother; 2021 Dec; 40(6):255-260. PubMed ID: 34958275
[TBL] [Abstract][Full Text] [Related]
13. A Cancer-Specific Monoclonal Antibody against HER2 Exerts Antitumor Activities in Human Breast Cancer Xenograft Models.
Kaneko MK; Suzuki H; Ohishi T; Nakamura T; Tanaka T; Kato Y
Int J Mol Sci; 2024 Feb; 25(3):. PubMed ID: 38339219
[TBL] [Abstract][Full Text] [Related]
14. Defucosylated Monoclonal Antibody (H
Suzuki H; Ohishi T; Nanamiya R; Kawada M; Kaneko MK; Kato Y
Curr Issues Mol Biol; 2023 Sep; 45(10):7734-7748. PubMed ID: 37886932
[TBL] [Abstract][Full Text] [Related]
15. Locally misfolded HER2 expressed on cancer cells is a promising target for development of cancer-specific antibodies.
Arimori T; Mihara E; Suzuki H; Ohishi T; Tanaka T; Kaneko MK; Takagi J; Kato Y
Structure; 2024 May; 32(5):536-549.e5. PubMed ID: 38460519
[TBL] [Abstract][Full Text] [Related]
16. Development of EMab-51, a Sensitive and Specific Anti-Epidermal Growth Factor Receptor Monoclonal Antibody in Flow Cytometry, Western Blot, and Immunohistochemistry.
Itai S; Kaneko MK; Fujii Y; Yamada S; Nakamura T; Yanaka M; Saidoh N; Handa S; Chang YW; Suzuki H; Harada H; Kato Y
Monoclon Antib Immunodiagn Immunother; 2017 Oct; 36(5):214-219. PubMed ID: 28891752
[TBL] [Abstract][Full Text] [Related]
17. Establishment of EMab-134, a Sensitive and Specific Anti-Epidermal Growth Factor Receptor Monoclonal Antibody for Detecting Squamous Cell Carcinoma Cells of the Oral Cavity.
Itai S; Yamada S; Kaneko MK; Chang YW; Harada H; Kato Y
Monoclon Antib Immunodiagn Immunother; 2017 Dec; 36(6):272-281. PubMed ID: 29090976
[TBL] [Abstract][Full Text] [Related]
18. Enhanced antitumor activity of trastuzumab emtansine (T-DM1) in combination with pertuzumab in a HER2-positive gastric cancer model.
Yamashita-Kashima Y; Shu S; Harada N; Fujimoto-Ouchi K
Oncol Rep; 2013 Sep; 30(3):1087-93. PubMed ID: 23783223
[TBL] [Abstract][Full Text] [Related]
19. Suppression of tumor growth in human gastric cancer with HER2 overexpression by an anti-HER2 antibody in a murine model.
Matsui Y; Inomata M; Tojigamori M; Sonoda K; Shiraishi N; Kitano S
Int J Oncol; 2005 Sep; 27(3):681-5. PubMed ID: 16077916
[TBL] [Abstract][Full Text] [Related]
20. Characterization of novel murine monoclonal antibodies directed against the extracellular domain of human HER2 tyrosine kinase receptor.
Kazemi T; Tahmasebi F; Bayat AA; Mohajer N; Khoshnoodi J; Jeddi-Tehrani M; Rabbani H; Shokri F
Hybridoma (Larchmt); 2011 Aug; 30(4):347-53. PubMed ID: 21851234
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
